Payment overview · 2025
General Payments
$513.04
20 reported records · 12 companies
Healthcare provider profile · identity verified
Nilesh Devabhai Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LUBBOCK, TX · NPI 1689638421
Verified facts
What the public records show
CMS Open Payments records show Nilesh Devabhai Patel, MD received $513.04 in general payments during 2025 across 20 reported records.
Stryker Corporation accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $130.51 | 25.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.94 | 16.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.14 | 15.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.58 | 7.3% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $33.54 | 6.5% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $33.38 | 6.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.23 | 4.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.91 | 4.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.72 | 4.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.73 | 3.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.70 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.66 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $513.04 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPACE Normalized: inspace |
Device | Stryker Corporation | $130.51 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.10 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.10 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.39 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.69 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $33.54 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $33.38 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 216 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 125 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 130 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 196 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
125 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
54 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
196 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
216 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
41 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 827 | 238 |
| Levothyroxine Sodium | Levothyroxine Sodium | 824 | 220 |
| Amlodipine Besylate | Amlodipine Besylate | 644 | 182 |
| Metformin Hcl | Metformin Hcl | 625 | 180 |
| Pantoprazole Sodium | Pantoprazole Sodium | 571 | 172 |
| Tramadol Hcl | Tramadol Hcl | 538 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 530 | 152 |
| Gabapentin | Gabapentin | 469 | 112 |
| Losartan Potassium | Losartan Potassium | 461 | 137 |
| Lisinopril | Lisinopril | 442 | 118 |
| Potassium Chloride | Potassium Chloride | 411 | 130 |
| Azithromycin | Azithromycin | 391 | 301 |
| Metoprolol Succinate | Metoprolol Succinate | 364 | 105 |
| Prednisone | Prednisone | 355 | 245 |
| Tamsulosin Hcl | Tamsulosin Hcl | 341 | 115 |
| Alprazolam | Alprazolam | 338 | 59 |
| Ozempic | Semaglutide | 332 | 58 |
| Omeprazole | Omeprazole | 316 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 303 | 122 |
| Furosemide | Furosemide | 289 | 95 |
| Zolpidem Tartrate | Zolpidem Tartrate | 279 | 55 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 255 | 51 |
| Meloxicam | Meloxicam | 241 | 58 |
| Montelukast Sodium | Montelukast Sodium | 238 | 81 |
| Pravastatin Sodium | Pravastatin Sodium | 225 | 67 |
| Eliquis | Apixaban | 216 | 43 |
| Simvastatin | Simvastatin | 216 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 206 | 62 |
| Mounjaro | Tirzepatide | 196 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 187 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 179 | 47 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 178 | 72 |
| Temazepam | Temazepam | 177 | 26 |
| Trazodone Hcl | Trazodone Hcl | 172 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 47 |
| Doxycycline Hyclate | Doxycycline Hyclate | 158 | 120 |
| Glimepiride | Glimepiride | 153 | 48 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 153 | 40 |
| Glipizide | Glipizide | 150 | 44 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 141 | 118 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 42 |
| Allopurinol | Allopurinol | 130 | 39 |
| Jardiance | Empagliflozin | 130 | 29 |
| Finasteride | Finasteride | 127 | 39 |
| Farxiga | Dapagliflozin Propanediol | 125 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 124 | 22 |
| Sertraline Hcl | Sertraline Hcl | 124 | 37 |
| Carvedilol | Carvedilol | 121 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 34 |
| Celecoxib | Celecoxib | 107 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 107 | 26 |
| Alendronate Sodium | Alendronate Sodium | 104 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 100 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 28 |
| Cephalexin | Cephalexin | 97 | 46 |
| Methylprednisolone | Methylprednisolone | 97 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 27 |
| Spironolactone | Spironolactone | 85 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 81 | 54 |
| Clonidine Hcl | Clonidine Hcl | 78 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 19 |
| Clonazepam | Clonazepam | 72 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 20 |
| Irbesartan | Irbesartan | 68 | 22 |
| Mirtazapine | Mirtazapine | 68 | 16 |
| Ondansetron Odt | Ondansetron | 64 | 41 |
| Ezetimibe | Ezetimibe | 63 | 17 |
| Pregabalin | Pregabalin | 62 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 12 |
| Atenolol | Atenolol | 57 | 18 |
| Levofloxacin | Levofloxacin | 57 | 43 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 55 | 15 |
| Azelastine Hcl | Azelastine Hcl | 54 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 54 | 19 |
| Memantine Hcl | Memantine Hcl | 52 | 13 |
| Sucralfate | Sucralfate | 52 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 13 |
| Donepezil Hcl | Donepezil Hcl | 46 | 15 |
| Nifedipine Er | Nifedipine | 46 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 11 |
| Fluconazole | Fluconazole | 44 | 25 |
| Meclizine Hcl | Meclizine Hcl | 44 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 28 |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 40 |
| Ventolin Hfa | Albuterol Sulfate | 41 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 15 |
| Diazepam | Diazepam | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 16 |
| Benazepril Hcl | Benazepril Hcl | 38 | 13 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 12 |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Estradiol | Estradiol | 32 | 13 |
| Nystatin | Nystatin | 32 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | 11 |
| Famotidine | Famotidine | 29 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | 14 |
| Valsartan | Valsartan | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | 14 |
| Ramipril | Ramipril | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 15 |
| Estradiol (Once Weekly) | Estradiol | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 21 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 21 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 13 |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | 11 |
| Topiramate | Topiramate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | 11 |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $513.04 · 20 records | Stryker Corporation | Dexcom G6 Transmitter, ELIQUIS, FARXIGA, INSPACE, JARDIANCE, MOUNJARO, OTEZLA, Ohtuvayre, QULIPTA, REPATHA, REXULTI, Senza, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error